Production (Stage)
Nexien BioPharma, Inc.
NXEN
$0.0145
$0.00552.63%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.80% | -23.44% | 63.01% | -62.59% | -117.14% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 2.33% | -28.33% | -81.82% | 432.26% | 72.22% |
| Total Other Non-Cash Items | 21.05% | 26.67% | -94.97% | 34.84% | 1,909.09% |
| Change in Net Operating Assets | 126.09% | -69.74% | 17.83% | 222.50% | -9.09% |
| Cash from Operations | 54.55% | -210.87% | 15.60% | 48.10% | -36.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -20.00% | 150.00% | 100.00% | -82.39% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20.00% | 150.00% | 100.00% | -82.39% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 294.44% | -550.00% | 113.56% | -179.73% | 148.05% |